Gerrit Jan Weverling

7.1k total citations · 1 hit paper
88 papers, 5.0k citations indexed

About

Gerrit Jan Weverling is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Gerrit Jan Weverling has authored 88 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Infectious Diseases, 35 papers in Epidemiology and 34 papers in Virology. Recurrent topics in Gerrit Jan Weverling's work include HIV Research and Treatment (32 papers), HIV/AIDS drug development and treatment (29 papers) and HIV/AIDS Research and Interventions (20 papers). Gerrit Jan Weverling is often cited by papers focused on HIV Research and Treatment (32 papers), HIV/AIDS drug development and treatment (29 papers) and HIV/AIDS Research and Interventions (20 papers). Gerrit Jan Weverling collaborates with scholars based in Netherlands, United States and United Kingdom. Gerrit Jan Weverling's co-authors include Joep M. A. Lange, Jaap Goudsmit, Suzanne Jurriaans, Peter Reiss, Ferdinand W N M Wit, Hanneke Schuitemaker, Jan W. Mulder, Roel A. Coutinho, Richard M. W. Hoetelmans and Ferdinand W.N.M. Wit and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Gerrit Jan Weverling

88 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study

2020 215 citations Mohsen Ghanbari, Gerrit Jan Weverling et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerrit Jan Weverling Netherlands	40	2.5k	1.6k	1.6k	640	584	88	5.0k
Jonathan B. Angel Canada	41	1.9k 0.8×	1.7k 1.1×	1.4k 0.9×	708 1.1×	365 0.6×	177	5.5k
Marshall J. Glesby United States	45	2.6k 1.0×	1.6k 1.0×	1.9k 1.2×	461 0.7×	483 0.8×	179	6.3k
Mauro Moroni Italy	42	2.4k 1.0×	2.0k 1.3×	1.3k 0.8×	720 1.1×	2.2k 3.8×	165	6.7k
Antonella Castagna Italy	38	3.4k 1.3×	2.5k 1.6×	1.5k 1.0×	531 0.8×	665 1.1×	340	5.7k
Guido Antonelli Italy	47	2.3k 0.9×	1.0k 0.6×	2.5k 1.6×	900 1.4×	1.0k 1.8×	371	7.4k
Massimo Andreoni Italy	37	3.0k 1.2×	1.6k 1.0×	2.0k 1.3×	385 0.6×	914 1.6×	315	5.3k
Eugenia Quirós-Roldán Italy	32	2.0k 0.8×	1.1k 0.7×	1.1k 0.7×	520 0.8×	484 0.8×	228	4.2k
Peter Skinhøj Denmark	43	2.1k 0.8×	974 0.6×	2.8k 1.8×	600 0.9×	492 0.8×	214	6.8k
Michael H. Grieco United States	28	3.8k 1.5×	2.3k 1.5×	2.6k 1.6×	589 0.9×	387 0.7×	87	6.7k
Paul R. Skolnik United States	35	1.9k 0.8×	1.8k 1.1×	1.5k 0.9×	256 0.4×	252 0.4×	77	4.2k

Countries citing papers authored by Gerrit Jan Weverling

Since Specialization

Citations

This map shows the geographic impact of Gerrit Jan Weverling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerrit Jan Weverling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerrit Jan Weverling more than expected).

Fields of papers citing papers by Gerrit Jan Weverling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerrit Jan Weverling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerrit Jan Weverling. The network helps show where Gerrit Jan Weverling may publish in the future.

Co-authorship network of co-authors of Gerrit Jan Weverling

This figure shows the co-authorship network connecting the top 25 collaborators of Gerrit Jan Weverling. A scholar is included among the top collaborators of Gerrit Jan Weverling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerrit Jan Weverling. Gerrit Jan Weverling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yaqub, Amber, Michelle M. J. Mens, J. Klap, et al.. (2022). Genome‐wide profiling of circulatory microRNAs associated with cognition and dementia. Alzheimer s & Dementia. 19(4). 1194–1203. 10 indexed citations

Zahn, Roland, Mo Weijtens, Maria Grazia Pau, et al.. (2012). Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species. PLoS ONE. 7(12). e44115–e44115. 42 indexed citations

Koudstaal, Wouter, Martin H. Koldijk, Just P. J. Brakenhoff, et al.. (2009). Pre‐ and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir. The Journal of Infectious Diseases. 200(12). 1870–1873. 39 indexed citations

Radošević, Katarina, Ariane Rodrı́guez, Ratna Mintardjo, et al.. (2008). Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Vaccine. 26(29-30). 3640–3646. 44 indexed citations

Havenga, Menzo, Wouter Koudstaal, Yevgeny Khinich, et al.. (2007). Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine. Vaccine. 25(49). 8338–8345. 23 indexed citations

Stewart, V. Ann, Shannon McGrath, Patrice Dubois, et al.. (2007). Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity toPlasmodium falciparumCS Compared to That with Either Malaria Vaccine Alone. Infection and Immunity. 75(5). 2283–2290. 77 indexed citations

Casula, Miriam, Gerrit Jan Weverling, Ferdinand W.N.M. Wit, et al.. (2005). Mitochondrial DNA and RNA Increase in Peripheral Blood Mononuclear Cells from HIV‐1–Infected Patients Randomized to Receive Stavudine‐Containing or Stavudine‐Sparing Combination Therapy. The Journal of Infectious Diseases. 192(10). 1794–1800. 36 indexed citations

Kuyl, Antoinette C. van der, Abeltje M. Polstra, Remco van den Burg, et al.. (2005). Cytomegalovirus and human herpesvirus 8 DNA detection in peripheral blood monocytic cells of AIDS patients: Correlations with the presence of Kaposi's sarcoma and CMV disease. Journal of Medical Virology. 76(4). 541–546. 8 indexed citations

Cahen, Djuna L., et al.. (2005). Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis. European Journal of Gastroenterology & Hepatology. 17(1). 103–108. 62 indexed citations

10.

Kuyl, Antoinette C. van der, Abeltje M. Polstra, Gerrit Jan Weverling, et al.. (2004). An IL-8 gene promoter polymorphism is associated with the risk of the development of AIDS-related Kaposi's sarcoma. AIDS. 18(8). 1206–1208. 24 indexed citations

11.

Meulen, Jan ter, Alexander B. H. Bakker, Edward N. van den Brink, et al.. (2004). Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. The Lancet. 363(9427). 2139–2141. 205 indexed citations

12.

Kempen, Anne Van, Johannes A. Romijn, An F.C. Ruiter, et al.. (2003). Alanine administration does not stimulate gluconeogenesis in preterm infants. Metabolism. 52(8). 945–949. 14 indexed citations

13.

Renwick, Neil, et al.. (2002). Vascular Endothelial Growth Factor Levels in Serum Do Not Increase Following HIV Type 1 and HHV8 Seroconversion and Lack Correlation with AIDS-Related Kaposi's Sarcoma. AIDS Research and Human Retroviruses. 18(10). 695–698. 6 indexed citations

14.

Wit, Ferdinand W N M, et al.. (2002). Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy. The Journal of Infectious Diseases. 186(1). 23–31. 260 indexed citations

15.

Reijers, Monique H., Hugo M. Weigel, Augustinus A. M. Hart, et al.. (2000). Toxicity and drug exposure in a quadruple drug regimen in HIV–1 infected patients participating in the ADAM study. AIDS. 14(1). 59–68. 51 indexed citations

16.

Gisolf, Elizabeth H., et al.. (2000). Risk Factors for Hepatotoxicity in HIV-1--Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine. Clinical Infectious Diseases. 31(5). 1234–1239. 75 indexed citations

17.

Meenhorst, Pieter L., Jan W. Mulder, Gerrit Jan Weverling, et al.. (2000). Value of Different Assays for Detection of Human Cytomegalovirus (HCMV) in Predicting the Development of HCMV Disease in Human Immunodeficiency Virus-Infected Patients. Journal of Clinical Microbiology. 38(2). 563–569. 23 indexed citations

18.

Meenhorst, Pieter L., Gerrit Jan Weverling, W. Pauw, et al.. (1999). Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients. AIDS. 13(18). 2533–2539. 5 indexed citations

19.

Frissen, P. H. J., et al.. (1996). Predictive Value for Survival of Soluble Tumor Necrosis Factor Receptors p55 and p75 During Zidovudine-Containing Treatment in Symptomatic Human Immunodeficiency Virus Type 1 Infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 12(5). 482–488. 5 indexed citations

20.

Louwerse, Elisabeth S., Patrick M. Bossuyt, Gerrit Jan Weverling, & J.M.B.V. de Jong. (1995). Mortality risk stratification in amyotrophic lateral sclerosis. Journal of the Neurological Sciences. 129. 27–27. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact